Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214

In the randomized, open-label, phase 3 CheckMate 214 trial, nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 wk for four doses, then nivolumab 3 mg/kg every 2 wk) had superior efficacy over sunitinib (SUN; 50 mg once daily, 4 wk on, 2 wk off) in patients with untreated In...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur Urol
Auteurs principaux: Escudier, Bernard, Motzer, Robert J., Tannir, Nizar M., Porta, Camillo, Tomita, Yoshihiko, Maurer, Matthew, McHenry, M. Brent, Rini, Brian I.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7521478/
https://ncbi.nlm.nih.gov/pubmed/31732098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2019.10.025
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires